Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTQYF7G)

• DTT Name: Cyclin-dependent kinase 7 (CDK7) DTT Info
• Gene Name: CDK7

Molecule-Related Drug & Molecule List

7 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[1]
Samuraciclib	DM54FQA	Breast cancer	2C60-2C65	Phase 1/2	[2]
BTX-A51	DMC8XHQ	Advanced solid tumour	2A00-2F9Z	Phase 1	[3]
LY3405105	DMB51K2	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
SY-1365	DMK48PM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
SY-5609	DMNW3LH	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]

6 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Oxazolyl methylthiothiazole derivative 1	DMZM6FW	N. A.	N. A.	Patented	[8]
PMID26161698-Compound-34	DMTIM1E	N. A.	N. A.	Patented	[8]
Pyrazolo-triazine derivative 1	DMTD3C1	N. A.	N. A.	Patented	[8]
Pyrazolo-triazine derivative 2	DML6V78	N. A.	N. A.	Patented	[8]
Roscovitine derivative 1	DMD1G3Z	N. A.	N. A.	Patented	[8]
Tricyclic benzimidazole derivative 1	DM5SD9E	N. A.	N. A.	Patented	[8]

2 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R547	DMK25FU	Advanced solid tumour	2A00-2F9Z	Discontinued in Phase 1	[1]
ZK 304709	DMJ9R4A	Advanced solid tumour	2A00-2F9Z	Discontinued in Phase 1	[1]

6 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2,5-dichloro-N-p-tolylthiophene-3-sulfonamide	DMU5J8Y	Discovery agent	N.A.	Investigative	[9]
NU6140	DMCUSG3	Discovery agent	N.A.	Investigative	[10]
PF-228	DM32FKD	Discovery agent	N.A.	Investigative	[11]
Phosphonothreonine	DMTFHPI	Discovery agent	N.A.	Investigative	[12]
RGB-286147	DMP08BY	Discovery agent	N.A.	Investigative	[13]
THZ1	DMU10FE	Nasopharyngeal carcinoma	2B6B	Investigative	[14]

References

• [1] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [2] The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer. Br J Cancer. 2023 Jun;128(12):2326-2337.
• [3] Clinical pipeline report, company report or official report of BioTheryX.
• [4] CDK7 inhibitors as anticancer drugs. Cancer Metastasis Rev. 2020 Sep;39(3):805-823.
• [5] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] Clinical pipeline report, company report or official report of Syros Pharmaceuticals.
• [8] Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
• [9] Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases, Bioorg. Med. Chem. Lett. 20(13):3863-3867 (2010).
• [10] Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation. Mol Cancer Ther. 2005 Sep;4(9):1328-37.
• [11] Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007 May 18;282(20):14845-52.
• [12] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [13] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [14] Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. Nature. 2014 Jul 31;511(7511):616-20.